Abstract
Introduction. Autoimmune hepatitis (AIH) is one of the autoimmune liver disorders recognized in children, along with autoimmune sclerosing cholangitis (ASC) and de novo AIH after liver transplant. This study aimed to assess the treatment in children with AIH, and to identify correlations with disease outcomes. Materials and method. In this retrospective study, we included 30 hospitalized children with AIH, followed-up in our clinic over six years. All patients met the International Autoimmune Hepatitis Group’s simplified diagnostic criteria (IAIHG criteria). Results. Pediatric patients with AIH were aged between 4 months old and 17 years and 8 months old, with a mean age of 6.5 years old. There were 19 girls and 11 boys. Most patients had an acute onset of the disease. Three patients developed acute liver failure. All patients had elevated transaminases and 16 patients had cholestasis. Most patients had increased IgG levels. There were 20 children with type I AIH with SMA and ANA, and 10 children with type II AIH with anti-LKM-1 and anti-LC-1. All patients received prednisone from the diagnosis. Fifteen patients required the addition of azathioprine. Full clinical recovery with a normal level of transaminases was achieved in 18 patients. Complete remission was achieved in 10 patients. Most children had a favorable outcome, with only five patients presenting cirrhosis. Two children died due to complications of autoimmune cirrhosis. Conclusions. The outcome of children with AIH treated with immediate immunosuppressive therapy is favorable, with good long-term survival rates and with a positive effect on the quality of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have